Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
Predicting response to cancer immunotherapy is still a challenge. Here, the authors show that their method of predicting MHC-binding peptides, combined with profiling anti-immunogenic mutations, can better predict the clinical benefit of immunotherapy.
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-14562-z |